The Mycotoxin Patulin Inhibits the Mitochondrial Carnitine/Acylcarnitine Carrier (SLC25A20) by Interaction with Cys136 Implications for Human Health

Int J Mol Sci. 2023 Jan 23;24(3):2228. doi: 10.3390/ijms24032228.

Abstract

The effect of mycotoxin patulin (4-hydroxy-4H-furo [3,2c] pyran-2 [6H] -one) on the mitochondrial carnitine/acylcarnitine carrier (CAC, SLC25A20) was investigated. Transport function was measured as [3H]-carnitineex/carnitinein antiport in proteoliposomes reconstituted with the native protein extracted from rat liver mitochondria or with the recombinant CAC over-expressed in E. coli. Patulin (PAT) inhibited both the mitochondrial native and recombinant transporters. The inhibition was not reversed by physiological and sulfhydryl-reducing reagents, such as glutathione (GSH) or dithioerythritol (DTE). The IC50 derived from the dose-response analysis indicated that PAT inhibition was in the range of 50 µM both on the native and on rat and human recombinant protein. The kinetics process revealed a competitive type of inhibition. A substrate protection experiment confirmed that the interaction of PAT with the protein occurred within a protein region, including the substrate-binding area. The mechanism of inhibition was identified using the site-directed mutagenesis of CAC. No inhibition was observed on Cys mutants in which only the C136 residue was mutated. Mass spectrometry studies and in silico molecular modeling analysis corroborated the outcomes derived from the biochemical assays.

Keywords: carnitine carrier; cysteines; inhibition; mitochondria; patulin.

MeSH terms

  • Animals
  • Carnitine / metabolism
  • Carnitine / pharmacology
  • Cysteine / metabolism
  • Escherichia coli / metabolism
  • Glutathione / metabolism
  • Humans
  • Membrane Transport Proteins
  • Patulin*
  • Rats
  • Sulfhydryl Reagents / pharmacology

Substances

  • Patulin
  • acylcarnitine
  • Cysteine
  • Sulfhydryl Reagents
  • Carnitine
  • Glutathione
  • SLC25A20 protein, human
  • Membrane Transport Proteins

Grants and funding

“SI.F.I.PA.CRO.DE.—Sviluppo e industrializzazione farmaci innovativi per terapia molecolare personalizzata PA.CRO.DE.” PON ARS01_00568 to CesareIndiveri granted by MUR (Ministry of University and Research) Italy.